Labeling compliance burden comments sought
This article was originally published in The Tan Sheet
Executive Summary
Roughly 500 nonprescription drugs introduced annually through new drug applications or abbreviated NDAs must comply with FDA's standardized format and content requirements for labeling marketed OTC drug products. In a June 3 Federal Register notice seeking comments on a proposed collection of information on industry's burden for compliance with the 1999 OTC labeling final rule, FDA says the Consumer Healthcare Products Association provided data for the estimate. The notice also says some 4,750 OTC sunscreen stock-keeping units have not complied with the labeling rule, but need to by a date the agency will set when it publishes a final rule for the OTC sunscreen monograph. FDA estimates firms need five hours to prepare labeling for OTC NDAs and ANDAs and two hours for sunscreen labeling prior to submitting the information to the agency. Monograph OTC drugs already must comply with the labeling rule. The deadline for comments is Aug. 3
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.